150 related articles for article (PubMed ID: 37544016)
1. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
Chu Y; Kordower JH
Mov Disord; 2023 Sep; 38(9):1728-1736. PubMed ID: 37544016
[TBL] [Abstract][Full Text] [Related]
2. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.
Chu Y; Bartus RT; Manfredsson FP; Olanow CW; Kordower JH
Brain; 2020 Mar; 143(3):960-975. PubMed ID: 32203581
[TBL] [Abstract][Full Text] [Related]
3. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.
Bartus RT; Kordower JH; Johnson EM; Brown L; Kruegel BR; Chu Y; Baumann TL; Lang AE; Olanow CW; Herzog CD
Neurobiol Dis; 2015 Jun; 78():162-71. PubMed ID: 25841760
[TBL] [Abstract][Full Text] [Related]
4. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
5. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Warren Olanow C; Bartus RT; Baumann TL; Factor S; Boulis N; Stacy M; Turner DA; Marks W; Larson P; Starr PA; Jankovic J; Simpson R; Watts R; Guthrie B; Poston K; Henderson JM; Stern M; Baltuch G; Goetz CG; Herzog C; Kordower JH; Alterman R; Lozano AM; Lang AE
Ann Neurol; 2015 Aug; 78(2):248-57. PubMed ID: 26061140
[TBL] [Abstract][Full Text] [Related]
6. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
[TBL] [Abstract][Full Text] [Related]
7. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
Bartus RT; Herzog CD; Chu Y; Wilson A; Brown L; Siffert J; Johnson EM; Olanow CW; Mufson EJ; Kordower JH
Mov Disord; 2011 Jan; 26(1):27-36. PubMed ID: 21322017
[TBL] [Abstract][Full Text] [Related]
8. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
10. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
Kasanga EA; Han Y; Navarrete W; McManus R; Shifflet MK; Parry C; Barahona A; Manfredsson FP; Nejtek VA; Richardson JR; Salvatore MF
Exp Neurol; 2023 Aug; 366():114435. PubMed ID: 37178997
[TBL] [Abstract][Full Text] [Related]
12. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
[TBL] [Abstract][Full Text] [Related]
13. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.
Marks WJ; Baumann TL; Bartus RT
Hum Gene Ther; 2016 Jul; 27(7):522-7. PubMed ID: 26711317
[TBL] [Abstract][Full Text] [Related]
15. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease.
Chu Y; Kordower JH
Neurobiol Dis; 2021 Jun; 153():105298. PubMed ID: 33684514
[TBL] [Abstract][Full Text] [Related]
16. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
Marks WJ; Bartus RT; Siffert J; Davis CS; Lozano A; Boulis N; Vitek J; Stacy M; Turner D; Verhagen L; Bakay R; Watts R; Guthrie B; Jankovic J; Simpson R; Tagliati M; Alterman R; Stern M; Baltuch G; Starr PA; Larson PS; Ostrem JL; Nutt J; Kieburtz K; Kordower JH; Olanow CW
Lancet Neurol; 2010 Dec; 9(12):1164-1172. PubMed ID: 20970382
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
Akerud P; Alberch J; Eketjäll S; Wagner J; Arenas E
J Neurochem; 1999 Jul; 73(1):70-8. PubMed ID: 10386956
[TBL] [Abstract][Full Text] [Related]
18. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Biju KC; Santacruz RA; Chen C; Zhou Q; Yao J; Rohrabaugh SL; Clark RA; Roberts JL; Phillips KA; Imam SZ; Li S
Neurosci Lett; 2013 Feb; 535():24-9. PubMed ID: 23295906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
